- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02625493
Patient Preference for Radial Versus Femoral Vascular Access (PREVAS)
Patient Preferences for Radial Versus Femoral Vascular Access Options by Coronary Angiography and Intervention
Study Overview
Detailed Description
Rationale: To explore patient preference for vascular access site in percutaneous coronary procedures, by assessing the perceived importance of benefits and risks of both transradial access and transfemoral access. In addition, direct preference for vascular access and preference for shared decision-making were evaluated.
Objective: To investigate the patient preference of vascular access -transradial versus transfemoral- in future percutaneous coronary procedures, by use of the Best-Worst Scaling.
Study design: Single-center, prospective, observational registry
Study population: A consecutive series of patients, who between June and August 2014, underwent elective coronary procedures at Thoraxcentrum Twente in Enschede.
Intervention: All subjects will receive a questionnaire containing basic baseline questions and a best-worst scaling scenario in which they were asked to indicate the most and least desirable characteristics of the vascular access approach.
Furthermore, their direct preference was asked and to which extent they preferred to participate in the decision-making process regarding the choice for vascular access route in future percutaneous coronary procedures.
Main study endpoints:
- The primary endpoint is the patient preference on specific treatment characteristics with regard to vascular access in coronary procedures.
Secondary endpoints include
- direct patient preference for transradial access or transfemoral access
- the valuation of participation in decision-making on the choice of vascular access together with the interventional cardiologist.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Enschede, Netherlands
- Medisch Spectrum Twente
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients who undergoing an elective coronary procedure at Thoraxcenteum Twente in the period of June 2014 until August 2014
Exclusion Criteria:
- Language barrier
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
study population
All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
|
Questionnaire containing a Best-worst Scaling scenario
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The best and worst treatment characteristics of transradial and transfemoral access, by using a software-generated Best-Worst Scaling Questionnaire - case 2
Time Frame: 30 days
|
Best-Worst Scaling Questionnaire will be used to assess which treatment characteristics patients find most and least desirable in percutaneous coronary procedures performed via transradial and transfemoral access.
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of times that patients prefer transradial in future percutaneous coronary procedure, when given a discrete choice via a questionnaire.
Time Frame: 30 days
|
When given the discrete choice, which access site patients would prefer in future percutaneous coronary procedures.
|
30 days
|
|
Percentage of patients that wants to be directly involved in the decision-making process when making the choice for access site in future coronary procedures, by use of a questionnaire.
Time Frame: 30 days
|
The valuation of participation in decision-making on the choice of vascular access together with the interventional cardiologist
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Harald Verheij, Research Manager
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Prevas-v2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.